Branislav Schifferdecker, MD
Interventional Cardiology · Oklahoma City, OKNPI 1013973304
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Boehringer Ingelheim at 48.3% of the total. 2025 is the largest year on record at $13,992, 2.9 times the $4,805 reported in 2019.
Across 561 payments — averaging $47.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$13K
- Medtronic$4K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Johnson & Johnson$1K
- plus $5K from 25 others
Across 51 payments — averaging $1848.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cvrx, Inc.$50K
- Esperion Therapeutics, Inc.$18K
- Novartis$16K
- Janssen Research & Development, LLC$8K
- CSL Behring$2K
- Kowa Research Institute, Inc.$1K
What the payments were for
- Speaking & faculty fees$12,37547%
- Travel & lodging$2,88511%
- Food & beverage$11,17342%
- Education$350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 87 | $12,789 |
| Medtronic(2 entities) | 22 | $3,785 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 87 | $1,695 |
| Lilly USA, LLC | 1 | $1,375 |
| AstraZeneca | 53 | $1,129 |
| Johnson & Johnson | 65 | $1,112 |
| Novartis | 46 | $667 |
| E.r. Squibb & Sons, L.L.C. | 59 | $620 |
| Pfizer | 48 | $558 |
| Boston Scientific | 4 | $381 |
| Amarin Pharma, Inc. | 21 | $365 |
| Abbott | 10 | $324 |
| Impulse Dynamics (USA) Inc. | 4 | $254 |
| Daiichi Sankyo Inc. | 7 | $216 |
| Philips North America LLC | 5 | $166 |
| Regeneron Healthcare Solutions, Inc. | 6 | $151 |
| Novo Nordisk | 3 | $143 |
| Scpharmaceuticals Inc. | 1 | $127 |
| Irhythm Technologies, Inc. | 7 | $113 |
| Abiomed | 2 | $108 |
| Kowa Pharmaceuticals America, Inc. | 5 | $81 |
| Asahi Intecc USA, Inc. | 2 | $60 |
| Merck | 3 | $59 |
| Esperion Therapeutics, Inc. | 4 | $51 |
| Amgen | 2 | $33 |
| Actelion Pharmaceuticals US, Inc. | 2 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| ZOLL Circulation Inc | 1 | $14 |
| Bayer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$12,975
- Reveal LINQ$2,402
- Micra$1,062
- OPTIMIZER$278
- WATCHMAN FLX$249
- XARELTO$149
- CAMZYOS$130
- FUROSCIX$127
- INJECTAFER$117
- WAINUA$116
- Ozempic$114
- ELIQUIS$112
- Vascepa$106
- HeartMate$101
How this compares
$26,468 in reported general payments places this provider in the 80th percentile of 110 interventional cardiology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,526 | $1,445,528 |
| JardianceEmpagliflozin | 555 | $539,128 |
| EntrestoSacubitril/Valsartan | 618 | $536,104 |
| FarxigaDapagliflozin Propanediol | 424 | $358,511 |
| XareltoRivaroxaban | 291 | $296,912 |
| Repatha SureclickEvolocumab | 97 | $80,917 |
| MultaqDronedarone Hcl | 59 | $68,831 |
| BrilintaTicagrelor | 80 | $64,821 |
| MounjaroTirzepatide | 45 | $63,132 |
| Rosuvastatin Calcium | 2,134 | $43,094 |
| Praluent PenAlirocumab | 40 | $32,756 |
| Metoprolol Succinate | 2,094 | $29,976 |
| Repatha SyringeEvolocumab | 22 | $25,736 |
| VascepaIcosapent Ethyl | 38 | $24,724 |
| ClopidogrelClopidogrel Bisulfate | 1,567 | $24,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $558 | $1,445,5281,526 claims |
| Boehringer IngelheimJardiance, Synjardy | $12,789 | $551,114569 claims |
| NovartisEntresto | $667 | $536,104618 claims |
| AstraZenecaFarxiga, Brilinta | $1,129 | $423,332504 claims |
| Johnson & JohnsonXarelto | $1,112 | $296,912291 claims |
| Sanofi-aventis U.S. LLCMultaq | $17 | $68,83159 claims |
| Lilly USA, LLCMounjaro | $1,375 | $63,13245 claims |
| Novo NordiskOzempic, Rybelsus | $143 | $44,15739 claims |
| Esperion Therapeutics, Inc.Nexlizet | $51 | $9,39212 claims |
| MerckJanuvia | $59 | $8,95214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 110 interventional cardiology providers in Oklahoma.
Other interventional cardiology in Oklahoma City
- George ChrysantOklahoma City$524K
- Jeffrey SparlingOklahoma City$231K
- Thomas McGarryOklahoma City$80K
- Usman BaberOklahoma City$76K
- Marcus SmithOklahoma City$67K
- Parker TruongOklahoma City$44K
- Mohammad GhaniOklahoma City$38K
- Timothy DalyOklahoma City$31K
- Mohit PahujaOklahoma City$21K
- Syed AliOklahoma City$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.